EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, JW (Cayman) Therapeutics Co's Enterprise Value is HK$322.0 Mil.
JW (Cayman) Therapeutics Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-533.9 Mil. Therefore, JW (Cayman) Therapeutics Co's EV-to-FCF for today is -0.60.
The historical rank and industry rank for JW (Cayman) Therapeutics Co's EV-to-FCF or its related term are showing as below:
HKSE:02126'
s EV-to-FCF Range Over the Past 10 Years
Min: -3.85 Med: -0.16 Max: 1.09
Current: -0.49
During the past 6 years, the highest EV-to-FCF of JW (Cayman) Therapeutics Co was 1.09. The lowest was -3.85. And the median was -0.16.
HKSE:02126's EV-to-FCF is ranked worse than 100% of 381
companies
in the Biotechnology industry
Industry Median: 7.56
vs HKSE:02126: -0.49
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of JW (Cayman) Therapeutics Co's EV-to-FCF
For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JW (Cayman) Therapeutics Co's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where JW (Cayman) Therapeutics Co's EV-to-FCF falls into.
JW (Cayman) Therapeutics Co's current Enterprise Value is HK$322.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. JW (Cayman) Therapeutics Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-533.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JW (Cayman) Therapeutics Co (HKSE:02126) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
JW (Cayman) Therapeutics Co's PE Ratio for today is calculated as:
JW (Cayman) Therapeutics Co's share price for today is HK$2.46.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. JW (Cayman) Therapeutics Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2.045.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
JW (Cayman) Therapeutics Co EV-to-FCF Related Terms
Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
JW (Cayman) Therapeutics Co (HKSE:02126) Business Description
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
JW (Cayman) Therapeutics Co (HKSE:02126) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02126 has been successfully added to your 